Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials
Inflammatory Bowel Diseases · 01.11.2026 · 32 (11) · 2193-2211
DOI: 10.1093/ibd/izag099 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 30.05.2026. Verfasst von Yuhong Yuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, London Health Science Centre, London, ON, Canada. Hauptthemen laut MEDLINE: Crohn Disease, Biological Products, Rectal Fistula. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Although several advanced therapies (ATs) for luminal Crohn’s disease (CD) have been approved, their efficacy for perianal fistulizing Crohn’s (pCD) has not been comprehensively reviewed.
Methods
A literature search was conducted in MEDLINE, Embase, and Cochrane CENTRAL up to October 2, 2025. Placebo-controlled randomized controlled trials (RCTs) evaluating treatment efficacy in pCD were included. Outcomes of interest were fistula response and fistula remission during the induction and maintenance trials. Pooled relative risks (RRs) were calculated using a random-effects model.
Results
Fourteen studies were eligible; only 4 RCTs were specifically designed for pCD, while the remainder were post hoc analyses of luminal CD studies with moderate to serious risk of bias. In pooled analyses of induction trials (4-28 weeks), ATs were associated with significantly higher induction of fistula response (RR 1.65, 95% CI 1.22-2.22) and remission (RR 1.91, 95% CI 1.37-2.67) compared to placebo. Infliximab and upadacitinib demonstrated significantly greater fistula response and remission, while ustekinumab significantly increased rates of fistula remission. For the maintenance phase (22-52 weeks), ATs were associated with significantly higher maintenance of fistula response (RR 1.54, 95% CI 1.21-1.97) and remission (RR 2.08, 95% CI 1.49-2.90) compared to placebo. Infliximab showed significantly greater maintenance of fistula response and remission compared with placebo, while adalimumab was superior for fistula remission.
Conclusion
Findings from our meta-analysis indicate that infliximab is effective for pCD, with limited evidence of benefit with adalimumab, ustekinumab, and upadacitinib. Well-designed RCTs investigating newer advanced therapies are needed to better guide targeted treatment strategies for this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, London Health Science Centre, London, ON, Canada.
- Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.
- Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
- Department of Gastroenterology and Hepatology, University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Université Grenoble Alpes/Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes/Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France.
- Program of Medicine, College of Medicine and Health Sciences, Abdullah Al Salem University, Kuwait City, Kuwait.
ORCID-Profile: Yuhong Yuan, Vipul Jairath, Jurij Hanzel, Marianne Hupe, Rocio Sedano, Mohammad Shehab, Olga Maria Nardone, Fernando Magro, Ailsa Hart, Sudheer Kumar Vuyyuru
Zitieren
APA
Yuan, Y., Jairath, V., Hanzel, J., Hupe, M., Sedano, R., Shehab, M., Nardone, O. M., Magro, F., Hart, A., & Vuyyuru, S. K. (2026). Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials. Inflammatory Bowel Diseases, 32(11), 2193-2211. https://doi.org/10.1093/ibd/izag099
Vancouver
Yuan Y, Jairath V, Hanzel J, Hupe M, Sedano R, Shehab M, et al. Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials. Inflammatory Bowel Diseases. 2026;32(11):2193-2211. doi:10.1093/ibd/izag099
BibTeX
@article{Yuan2026,
author = {Yuan, Yuhong and Jairath, Vipul and Hanzel, Jurij and Hupe, Marianne and Sedano, Rocio and Shehab, Mohammad and Nardone, Olga Maria and Magro, Fernando and Hart, Ailsa and Vuyyuru, Sudheer Kumar},
title = {Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {11},
pages = {2193--2211},
doi = {10.1093/ibd/izag099}
}
EUVIMED